众生药业
(002317)
| 流通市值：167.86亿 | | | 总市值：187.32亿 |
| 流通股本：7.62亿 | | | 总股本：8.50亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,888,753,875.6 | 1,299,729,912.96 | 634,261,440.11 | 2,467,418,394.64 |
| 营业收入 | 1,888,753,875.6 | 1,299,729,912.96 | 634,261,440.11 | 2,467,418,394.64 |
| 二、营业总成本 | 1,625,683,280.09 | 1,094,636,663.42 | 546,759,207.07 | 2,228,489,469.54 |
| 营业成本 | 816,027,661.18 | 545,022,213.03 | 275,368,528.16 | 1,084,821,829.52 |
| 税金及附加 | 14,251,933.37 | 10,380,674.13 | 6,347,330.99 | 21,454,071.28 |
| 销售费用 | 641,202,996.53 | 437,876,903.25 | 218,567,447.02 | 850,433,612.18 |
| 管理费用 | 99,086,287 | 66,235,038.78 | 30,575,841.15 | 151,749,299.47 |
| 研发费用 | 59,919,853.27 | 37,973,825.03 | 15,923,565.59 | 111,203,585.62 |
| 财务费用 | -4,805,451.26 | -2,851,990.8 | -23,505.84 | 8,827,071.47 |
| 其中:利息费用 | 3,530,303.79 | 3,140,527.31 | 3,046,387.16 | 25,345,328.45 |
| 其中:利息收入 | 7,387,135.77 | 5,727,293.03 | 2,932,282.83 | 18,767,667.78 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -7,024,206.21 | -6,347,793.14 | 966,814.44 | -18,219,305.06 |
| 加:投资收益 | 12,824,619.97 | 9,921,614.62 | 4,179,582.72 | 24,869,018.33 |
| 资产处置收益 | 5,198,596.9 | 171,158.15 | -4,745.46 | 28,462.2 |
| 资产减值损失(新) | -2,094,559.03 | -1,643,583.34 | 0 | -546,680,714.81 |
| 信用减值损失(新) | -6,276,546.77 | -8,102,778.27 | -2,417,375.49 | -5,662,803.76 |
| 其他收益 | 23,040,330.31 | 17,464,802.88 | 9,079,567.1 | 26,784,475.09 |
| 四、营业利润 | 288,738,830.68 | 216,556,670.44 | 99,306,076.35 | -279,951,942.91 |
| 加:营业外收入 | 159,271.57 | 76,554.05 | 10,577.97 | 173,047.24 |
| 减:营业外支出 | 1,561,786.21 | 888,077.67 | 54,383.25 | 56,102,790.83 |
| 五、利润总额 | 287,336,316.04 | 215,745,146.82 | 99,262,271.07 | -335,881,686.5 |
| 减:所得税费用 | 41,838,658.7 | 30,923,517.53 | 17,814,054.06 | 38,081,795.6 |
| 六、净利润 | 245,497,657.34 | 184,821,629.29 | 81,448,217.01 | -373,963,482.1 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 245,497,657.34 | 184,821,629.29 | 81,448,217.01 | -373,963,482.1 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 250,578,030.92 | 187,895,838.14 | 82,611,839.1 | -299,157,116.72 |
| 少数股东损益 | -5,080,373.58 | -3,074,208.85 | -1,163,622.09 | -74,806,365.38 |
| 扣除非经常损益后的净利润 | 245,594,335.52 | 186,564,655.05 | 78,434,825.55 | -260,312,696.31 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.3 | 0.22 | 0.1 | -0.36 |
| (二)稀释每股收益 | 0.3 | 0.22 | 0.1 | -0.36 |
| 八、其他综合收益 | -6,583,447.99 | -5,337,076.39 | -2,834,799.65 | -2,507,517.14 |
| 归属于母公司股东的其他综合收益 | -6,583,447.99 | -5,337,076.39 | -2,834,799.65 | -2,507,517.14 |
| 九、综合收益总额 | 238,914,209.35 | 179,484,552.9 | 78,613,417.36 | -376,470,999.24 |
| 归属于母公司股东的综合收益总额 | 243,994,582.93 | 182,558,761.75 | 79,777,039.45 | -301,664,633.86 |
| 归属于少数股东的综合收益总额 | -5,080,373.58 | -3,074,208.85 | -1,163,622.09 | -74,806,365.38 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |